|
[1]European Association for The Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
|
|
[2]KAMATH PS,WIESNER RH,MALINCHOC M,et al.A model to predict survival in patients with end-stage liver disease[J].Hepatology,2001,33(2):464-470.
|
|
[3]DURAND F,VALLA D.Assessment of the prognosis of cirrhosis:Child-Pugh versus MELD[J].J Hepatol,2005,42 Suppl(1):s100-s107.
|
|
[4] KIM HJ,LEE HW.Important predictor of mortality in patients with end-stage liver disease[J].Clin Mol Hepatol,2013,19(2):105-115.
|
|
[5]D'AMICO G,GARCIA-TSAO G,PAGLIARO L.Natural history and prognostic indicators of survival in cirrhosis:A systematic review of 118 studies[J].J Hepatol,2006,44(1):217-231.
|
|
[6]ARVANITI V,D'AMICO G,FEDE G,et al.Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J].Gastroenterology,2010,139(4):1246-1256.
|
|
[7]FEDE G,D'AMICO G,ARVANITI V,et al.Renal failure and cirrhosis:A systematic review of mortality and prognosis[J].J Hepatol,2012,56(4):810-818.
|
|
[8] KNODELL RG,ISHAK KG,BLACK WC,et al.Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J].Hepatology,1981,1(5):431-435.
|
|
[9]BEDOSSA P,POYNARD T.An algorithm for the grading of activity in chronic hepatitis C.The METAVIR Cooperative Study Group[J].Hepatology,1996,24(2):289-293.
|
|
[10]ISHAK K,BAPTISTA A,BIANCHI L,et al.Histological grading and staging of chronic hepatitis[J].J Hepatol,1995,22(6):696-699.
|
|
[11]KIM MY,CHO MY,BAIK SK,et al.Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension[J].J Hepatol,2011,55(5):1004-1009.
|
|
[12]KIM SU,OH HJ,WANLESS IR,et al.The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis[J].J Hepatol,2012,57(3):556-563.
|
|
[13]BEDOSSA P.Reversibility of hepatitis B virus cirrhosis after therapy:who and why?[J].Liver Int,2015,35(Suppl 1):78-81.
|
|
[14]XU S,WANG Y,TAI DC,et al.q Fibrosis:a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J].JHepatol,2014,61(2):260-269.
|
|
[15] WANG Y,HOU JL.Fibrosis assessment:impact on current management of chronic liver disease and application of quantitative invasive tools[J].Hepatol Int,2016,10(3):448-461.
|
|
[16]Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[17]TERRAULT NA,BZOWEJ NH,CHANG KM,et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology,2016,63(1):261-283.
|
|
[18] Chinese Society of Hepatology and Chinese Society of Infectious Disease,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2010,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2010,27(1):Ⅰ-ⅩⅥ.
|
|
[19]LOK AS,Mc MAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):661-662.
|
|
[20] SARIN SK,KUMAR M,LAU GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int,2016,10(1):1-98.
|
|
[21] World Health Organization.Guidelines for the screening,care and treatment of persons with hepatitis B infection[R].Geneva:World Health Organization,2015.
|
|
[22]SINN DH,LEE J,GOO J,et al.Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load[J].Hepatology,2015,62(3):694-701.
|
|
[23]DIENSTAG JL,GOLDIN RD,HEATHCOTE EJ,et al.Histological outcome during long-term lamivudine therapy[J].Gastroenterology,2003,124(1):105-117.
|
|
[24]RIZZETTO M,TASSOPOULOS NC,GOLDIN RD,et al.Extended lamivudine treatment in patients with HBe Ag-negative chronic hepatitis B[J].J Hepatol,2005,42(2):173-179.
|
|
[25]HADZIYANNIS SJ,TASSOPOULOS NC,HEATHCOTE EJ,et al.Long-term therapy with adefovir dipivoxil for HBe Ag-negative chronic hepatitis B for up to 5 years[J].Gastroenterology,2006,131(6):1743-1751.
|
|
[26]CHANG TT,LIAW YF,WU SS,et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology,2010,52(3):886-893.
|
|
[27]MARCELLIN P,GANE E,BUTI M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study[J].Lancet,2013,381(9865):468-475.
|
|
[28]LIAW YF.Reversal of cirrhosis:an achievable goal of hepatitis B antiviral therapy[J].J Hepatol,2013,59(4):880-881.
|
|
[29] LOK AS.Hepatitis:Long-term therapy of chronic hepatitis B reverses cirrhosis[J].Nat Rev Gastroenterol Hepatol,2013,10(4):199-200.
|
|
[30] LIAW YF,SUNG JJ,CHOW WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl JMed,2004,351(15):1521-1531.
|
|
[31]PENG CY,CHIEN RN,LIAW YF.Hepatitis B virus-related decompensated liver cirrhosis:benefits of antiviral therapy[J].J Hepatol,2012,57(2):442-450.
|
|
[32]JANG JW,CHOI JY,KIM YS,et al.Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis[J].Hepatology,2015,61(6):1809-1820.
|
|
[33]PAPATHEODORIDIS GV,CHAN HL,HANSEN BE,et al.Risk of hepatocellular carcinoma in chronic hepatitis B:assessment and modification with current antiviral therapy[J].J Hepatol,2015,62(4):956-967.
|
DownLoad: